The effectiveness of Entecavir on serum TGF-β1 in patients with decompensated cirrhosis
10.3760/cma.j.issn.1008-6706.2014.07.029
- VernacularTitle:恩替卡韦对失代偿期乙型肝炎肝硬化患者血清转化生长因子-β1的影响
- Author:
Tong ZOU
;
Caihong CHEN
- Publication Type:Journal Article
- Keywords:
Entecavir;
Transforming growth factor beta;
Liver cirrhosis;
Hepatitis B
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;(7):1027-1028
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the the effectiveness of Entecavir on serum transforming growth factor-β1 (TGF-β1) in patients with decompensated cirrhosis .Methods Eighty patients with decompensated cirrhosis were randomly divided into two groups ,the control group(n=40 cases) and the observation group (n=40 cases).The pa-tients in the control group were treated through the conventional treatmeat ,while the patients in the observation group were treated through the conventional treatment plus entecavir .They were treated for 24 weeks.Liver function,HBV DNA and serum TGF-β1 were detected.Results ALT,Tbil and ALB were improved after treatment in both groups (t=6.724,13.306,3.064,4.172,2.924,3.172,all P<0.05).They were more significantly improved in the obser-vation group than that in the control group (t=2.469,2.160,3.064,all P<0.05).HBV-DNA negative rate in the observation group was higher these in the control group (χ2 =4.82,P<0.05).Serum TGF-β1 in both groups were decreased after treatment(t=6.842,8.062,all P<0.01).There was a significant difference between two groups (t=3.178,P<0.05).Conclusion Entecavir can decrease serum TGF-β1 in patients with decompensated cirrhosis .
